Skip to content
Screener

Gyre Therapeutics, Inc. GYRE Q1 2026 earnings

Reported May 7, 2026 · Before market open

Revenue$22.5MMiss by $9.1M
EPS-$0.05Beat by $0.01
Revenue estimate$31.6M
EPS estimate-$0.06

Next report

Nov 6, 2026 (in 2 months)
Revenue estimate$28.4M
EPS estimate-$0.15

Financials

Q1 2026

Income statement

See full
Revenue$22.5M+2.1%
Gross profit$21.3M+0.6%
Operating income-$9.4M-512%
Net income-$8.7M-422%
EPS (diluted)-$0.10—

Balance sheet

See full
Cash & equivalents$37.5M+149%
Total debt$823.0K-48.1%
Total equity$101.3M+48.7%
Total assets$162.0M+24.8%

Cash flow

See full
Operating cash flow$3.2M+2,565%
CapEx$178.0K+45.9%
Free cash flow$3.0M+1,296%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$636.46M-11.9%
Enterprise value$599.78M-15.4%
P/S5.3×-1.9×

Profitability

See full
Gross margin95.2%-1.0pp
Operating margin-3.8%-14.1pp
Net margin-5.3%-12.6pp
FCF margin2.6%—

Returns & leverage

See full
Return on equity-7.5%-19.3pp
Debt / equity0×0.0×
Current ratio4.6×+1.0×

Segments

By product

See full
Contiva$849.0+204%
Etorel$672.0—
Other Product$31.0-57.5%

By segment

See full
Gyre Pharmaceuticals$22.5M+2.1%
Gyre-—

FAQ

When did Gyre Therapeutics, Inc. report Q1 2026 earnings?
Gyre Therapeutics, Inc. (GYRE) reported Q1 2026 earnings on May 7, 2026 before market open.
What were Gyre Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Gyre Therapeutics, Inc. reported revenue of $22.5M and eps of $-0.05 for Q1 2026.
Did Gyre Therapeutics, Inc. beat estimates in Q1 2026?
Revenue missed the consensus estimate of $31.6M by $9.1M. EPS beat the consensus estimate of $-0.06 by $0.01.
How did Gyre Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 2.1% from $22.1M a year earlier.
Where can I find Gyre Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001140361-26-018716) and the 10-Q periodic report (0001193125-26-214676) directly on SEC EDGAR. The filing index links above go to sec.gov.